ONVO
Organovo Holdings, Inc. [ONVO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ONVO Stock Summary
In the News
ONVO Financial details
Company Rating
-
Market Cap
10.14M
Income
-18.62M
Revenue
242K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
11 Jul 2024
P/E
-0.55
Forward P/E
-
PEG
-0.09
P/S
27.38
P/B
1.18
P/C
-
P/FCF
-0.61
Quick Ratio
4.8
Current Ratio
5.19
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.12
EPS next Y
-
EPS next Q
-
EPS this Y
50%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-15.59%
Revenue last 5Y
-34.59%
Revenue Q/Q
-
EPS Q/Q
-13.04%
-
-
-
-
SMA20
6.56%
SMA50
-67.34%
SMA100
-48.41%
Inst Own
-
Inst Trans
-
ROA
-163%
ROE
-126%
ROC
-2.03%
Gross Margin
100%
Oper. Margin
-5285%
Profit Margin
-4942%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.89-2.24
52W High
-
52W Low
-
RSI
47.08
Rel Volume
0.84
Avg Volume
102.9K
Volume
86.54K
Perf Week
1.01%
Perf Month
-5.66%
Perf Quarter
-
Perf Half Y
-51.22%
-
-
-
-
Beta
0.904
-
-
Volatility
0.06%, 0.14%
Prev Close
-3.38%
Price
2
Change
2.56%
Company Profile
- Volume Average 102.9K
- Market Capitalization 10.14M
- Employee 18
- CEO Mr. Keith E. Murphy
- Headquarters Solana Beach,CA,US
- IPO Date 2012-02-14
-
Website
https://www.organovo.com 
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
